Banarian Nordic Res (BVNKF) 44.5000 $BVNKF
Bavarian Nordic issues Financial Calendar for 2016
Thomson Reuters ONE - Fri Sep 11, 1:30AM CDT
COPENHAGEN, Denmark - September 11, 2015 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced its financial calendar for the year 2016.
Bavarian Nordic Announces First Half 2015 Results
Thomson Reuters ONE - Tue Aug 25, 12:02AM CDT
COPENHAGEN, Denmark, August 25, 2015 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today publishes its interim financial results for the first half of 2015. Revenue for the period was DKK 624 million (2014: DKK 450 million), the income before interest and tax (EBIT) was a profit of DKK 85 million (2014: DKK 70 million loss) and the net profit was DKK 107 million (2014: DKK 54 million loss). Financial expectations for the full year are maintained.
Bavarian Nordic to Host First Half 2015 Results Conference Call
Thomson Reuters ONE - Wed Aug 19, 10:30AM CDT
COPENHAGEN, Denmark - August 19, 2015 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) will announce its 2015 first half results on Tuesday, August 25, 2015.
Bavarian Nordic Initiates Phase 1 Clinical Trial of MVA-BN(r) in Respiratory Syncitial Virus (RSV)
GlobeNewswire - Tue Aug 18, 9:09AM CDT
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced the initiation of a Phase 1 clinical study of its MVA-BN RSV vaccine candidate against respiratory syncytial virus (RSV), the first study to evaluate the vaccine candidate in humans.
Metastatic Hormone Refractory Prostate Cancer Pipeline Review, H1 2015 - Summarizes all the Dormant and Discontinued Pipeline Projects
M2 - Mon Aug 17, 8:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ffhfkg/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2015" report to their offering. Summary This, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2015', provides an overview of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and enlists all their major and minor projects Companies Mentioned - AB Science - AbbVie Inc. - Adamis Pharmaceuticals Corporation - Advaxis, Inc. - Ambrx, Inc. - Amgen Inc. - Arrowhead Research Corporation - AstraZeneca Plc - ATLAB Pharma SAS - Bavarian Nordic A/S - Bellicum Pharmaceuticals, Inc. - BIND Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - CellCentric Ltd - DexTech Medical AB - Eli Lilly and Company - Emergent BioSolutions Inc. - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - GenSpera, Inc. - GlaxoSmithKline Plc - GTx, Inc. - Johnson & Johnson - Karyopharm Therapeutics, Inc. - Medivation, Inc. - Millennium Pharmaceuticals, Inc. - NewLink Genetics Corporation - Novartis AG - Oncogenex Pharmaceuticals, Inc. - Oncolytics Biotech Inc. - Onyx Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/ffhfkg/metastatic
ARWR: 6.40 (+0.68), AMBX: (), ADMP: 4.48 (+0.18), MDVN: 95.48 (-0.65), JNJ: 92.93 (+0.21), NLNK: 51.03 (+1.84), ABBV: 59.35 (-0.23), ADXS: 16.51 (+0.55), ONCY: 0.58 (-0.04), EBS: 32.58 (+0.39), AMGN: 153.21 (+0.07), BIND: 5.05 (+0.13), LLY: 81.80 (+0.96), BMY: 59.22 (+0.47), GSK: 40.26 (+0.02), GTXI: 0.86 (+0.01), BLCM: 17.05 (-0.48), AZN: 33.30 (+0.02), CELGZ: 1.93 (+0.07), KPTI: 14.95 (+0.41), NVS: 96.55 (+0.28)
Metastatic Breast Cancer - Pipeline Review, H1 2015 - Reviews Key Pipeline Products Under Drug Profile Section
M2 - Fri Aug 14, 8:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2kdtzh/metastatic_breast) has announced the addition of the "Metastatic Breast Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Breast Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Key Topics Covered: - Introduction - Metastatic Breast Cancer Overview - Therapeutics Development - Therapeutics under Development by Companies - Therapeutics under Investigation by Universities/Institutes - Pipeline Products Glance - Products under Development by Companies - Products under Investigation by Universities/Institutes - Companies Involved in Therapeutics Development - Therapeutics Assessment - Drug Profiles - Recent Pipeline Updates - Dormant Projects - Discontinued Products - Product Development Milestones Companies Mentioned - AbbVie Inc. - Advaxis, Inc. - Advenchen Laboratories, LLC - AlphaVax, Inc. - Amarna Therapeutics B.V. - Amgen Inc. - AngioGenex, Inc. - Aphios Corporation - arGEN-X BV - Aslan Pharmaceuticals Pte. Ltd. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Bavarian Nordic A/S - Bayer AG - BIOCAD - Biocon Limited - BioMarin Pharmaceutical Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CASI Pharmaceuticals Inc. - Celgene Corporation - Celldex Therapeutics, Inc. - Celltrion, Inc. - Corcept Therapeutics Incorporated - Curadis GmbH - Daiichi Sankyo Company, Limited - Deciphera Pharmaceuticals, LLC - Dompe Farmaceutici S.p.A. - Eisai Co., Ltd. - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/2k...tic_breast
ADXS: 16.51 (+0.55), BMRN: 132.88 (-0.20), CLDX: 15.45 (+0.53), AMGN: 153.21 (+0.07), LLY: 81.80 (+0.96), CASI: 1.11 (-0.11), BMY: 59.22 (+0.47), AZN: 33.30 (+0.02), AVEO: 1.36 (unch), ABBV: 59.35 (-0.23), CORT: 5.06 (+0.01), CELGZ: 1.93 (+0.07)
Colon Cancer Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Colon Cancer and Enlists all Their Major and Minor Projects
M2 - Fri Aug 14, 8:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6lqjnr/colon_cancer) has announced the addition of the "Colon Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Colon Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colon Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Colon Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities Key Topics Covered: - Introduction - Colon Cancer Overview - Therapeutics Development - Therapeutics under Development by Companies - Therapeutics under Investigation by Universities/Institutes - Pipeline Products Glance - Products under Development by Companies - Products under Investigation by Universities/Institutes - Companies Involved in Therapeutics Development - Therapeutics Assessment - Drug Profiles - Recent Pipeline Updates - Dormant Projects - Discontinued Products - Product Development Milestones Companies Mentioned - Aduro BioTech, Inc. - Advanced Proteome Therapeutics Corporation - Advenchen Laboratories, LLC - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alethia Biotherapeutics Inc. - AlphaVax, Inc. - Ambrx, Inc. - Anavex Life Sciences Corp. - AndroScience Corporation - ANP Technologies, Inc. - Aphios Corporation - Apogenix GmbH - Aposense Ltd. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bavarian Nordic A/S - Bio-Path Holdings, Inc. - Bioncotech Therapeutics S.L. - Bionomics Limited - Carna Biosciences, Inc. - Celyad - Cold Genesys, Inc. For more information visit http://www.researchandmarkets.com/research/6l...lon_cancer
ADRO: 20.40 (+0.27), BPTH: 1.14 (-0.03), AMBX: (), AZN: 33.30 (+0.02), CYAD: 42.26 (-0.69)
Colorectal Cancer - Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Colorectal Cancer
M2 - Fri Aug 14, 5:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dvsdxp/colorectal_cancer) has announced the addition of the "Colorectal Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Colorectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colorectal Cancer and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - A review of the Colorectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Key Topics Covered: - Colorectal Cancer Overview - Therapeutics Development - Therapeutics under Development by Companies - Therapeutics under Investigation by Universities/Institutes - Pipeline Products Glance - Products under Development by Companies - Products under Investigation by Universities/Institutes - Companies Involved in Therapeutics Development - Therapeutics Assessment - Drug Profiles - Recent Pipeline Updates - Dormant Projects - Discontinued Products - Product Development Milestones Companies Mentioned - 2cureX ApS - 3-V Biosciences, Inc. - 4SC AG - AB Science - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Adamed Sp. z o.o. - Advaxis, Inc. - Advenchen Laboratories, LLC - Aeterna Zentaris Inc. - Alchemia Limited - Allinky Biopharma - Amgen Inc. - Angiogene Pharmaceuticals Limited - Antibe Therapeutics, Inc. - Aphios Corporation - Arisaph Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Bavarian Nordic A/S - Bayer AG - Beta Cat Pharmaceuticals, LLC - Biocon Limited - Bionomics Limited - BioNovion B.V. - Biothera, Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company For more information visit http://www.researchandmarkets.com/research/dv...tal_cancer
ADXS: 16.51 (+0.55), ARQL: 1.71 (-0.01), AMGN: 153.21 (+0.07), BMY: 59.22 (+0.47), ATNM: 2.44 (+0.07), AZN: 33.30 (+0.02), AVEO: 1.36 (unch), ABBV: 59.35 (-0.23), ARRY: 5.88 (-0.05)
Respiratory Syncytial Virus (RSV) Infections: Pipeline Review, H1 2015 - Summarizes all the Dormant and Discontinued Pipeline Projects
M2 - Thu Aug 13, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fswgvd/respiratory) has announced the addition of the "Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Respiratory Syncytial Virus (RSV) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Respiratory Syncytial Virus (RSV) Infections and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Respiratory Syncytial Virus (RSV) Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Respiratory Syncytial Virus (RSV) Infections and enlists all their major and minor projects Companies Mentioned - 3-V Biosciences, Inc. - Ablynx NV - ADMA Biologics, Inc. - Agilvax, Inc. - AlphaVax, Inc. - AmVac AG - Aridis Pharmaceuticals LLC - Artificial Cell Technologies, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Bavarian Nordic A/S - Biota Pharmaceuticals, Inc. - Celltrion, Inc. - Codagenix, Inc. - Crucell N.V. - CureVac GmbH - Emergent BioSolutions Inc. - Evec, Inc. - F. Hoffmann-La Roche Ltd. - GenVec, Inc. - Gilead Sciences, Inc. - GlaxoSmithKline Plc - Humabs BioMed SA - iBio, Inc. - Immunovaccine, Inc. - Johnson & Johnson - Kineta, Inc. - MedImmune, LLC - Medivir AB - Merck & Co., Inc. - Microbiotix, Inc. - MSM Protein Technologies, Inc. - Mucosis B.V. - NanoBio Corporation For more information visit http://www.researchandmarkets.com/research/fs...espiratory
ADMA: 9.35 (+0.36), EBS: 32.58 (+0.39), BOTA: 2.08 (-0.08), GSK: 40.26 (+0.02), JNJ: 92.93 (+0.21), GILD: 109.63 (+2.38), MRK: 52.09 (-0.63), AZN: 33.30 (+0.02), IBIO: 0.70 (-0.01)
Kerrisdale Capital Announces Follow-Up Conference Call to Discuss Short Thesis on Bavarian Nordic A/S
PR Newswire Europe - Wed Aug 12, 1:30AM CDT
Kerrisdale Capital, a private investment manager, will host a follow-up conference call on Tuesday, August 18th, at 11:00am EDT / 17:00 CEST, to further discuss its analysis of Bavarian Nordic A/S, whose prostate-cancer treatment candidate, Prostvac-VF, Kerrisdale believes is ineffective. The speakers will review the available clinical data on Prostvac and competing prostate-cancer vaccines from the last 15 years. They will also discuss recent developments affecting the commercial prospects of Bavarian Nordic's Ebola and smallpox vaccines.
Bladder Cancer Pipeline Review, H1 2015 - 80 Companies & 119 Drug Profiles
M2 - Fri Jul 31, 8:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/shdv3w/bladder_cancer) has announced the addition of the "Bladder Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bladder Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bladder Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - Advaxis, Inc. - Alligator Bioscience AB - Alnylam Pharmaceuticals, Inc. - Altor BioScience Corporation - Amgen Inc. - AndroScience Corporation - APIM Therapeutics AS - Arno Therapeutics, Inc. - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - AuraSense Therapeutics, LLC - AVEO Pharmaceuticals, Inc. - AvidBiotics Corp. - Bavarian Nordic A/S - Bayer AG - BioCancell Ltd - Bioncotech Therapeutics S.L. - Biotest AG - cCAM Biotherapeutics Ltd. - Celgene Corporation - Cold Genesys, Inc. - Daiichi Sankyo Company, Limited - Dompe Farmaceutici S.p.A. - DormaTarg, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EntreChem, S.L. - Esperance Pharmaceuticals, Inc. - Evotec AG - F. Hoffmann-La Roche Ltd. - Gene Signal International SA - Genmab A/S - GlaxoSmithKline Plc - Heat Biologics, Inc. For more information visit http://www.researchandmarkets.com/research/sh...der_cancer
HTBX: 4.52 (+0.11), ADXS: 16.51 (+0.55), AMGN: 153.21 (+0.07), LLY: 81.80 (+0.96), GSK: 40.26 (+0.02), AZN: 33.30 (+0.02), AVEO: 1.36 (unch), CELGZ: 1.93 (+0.07)
Bavarian Nordic Announces Initiation of NCI-sponsored Phase 2 Study of PROSTVAC in Patients with Localized Prostate Cancer
Thomson Reuters ONE - Fri Jul 24, 12:31AM CDT
- Multi-center, placebo-controlled study designed to explore PROSTVAC(R) in patients undergoing active surveillance
Bavarian Nordic Announces that the Oxford Vaccines Group has Initiated a Phase 2 Study of the Ebola Prime-Boost Vaccine Regimen Combining MVA-BN(r) Filo and Janssen's AdVac(r) Technology
GlobeNewswire - Wed Jul 15, 1:10AM CDT
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the Oxford Vaccines Group has initiated a Phase 2 clinical study of the Ebola prime-boost vaccine regimen that combines Bavarian Nordic's MVA-BN Filo vaccine with the Ad26.ZEBOV vaccine from the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen). The first volunteers have received their initial vaccine dose.
JNJ: 92.93 (+0.21)
Bavarian Nordic Receives Order for IMVAMUNE(R) Smallpox Vaccine from the U.S. Government Valued at USD 133 Million
Thomson Reuters ONE - Tue Jul 07, 12:01AM CDT
- Bulk supply order will help maintain current stockpile and serves as a precursor for future contracts for freeze-dried formulation of IMVAMUNE
Bavarian Nordic Announces Option Exercise by U.S. Government for Development of Filovirus Vaccine
Thomson Reuters ONE - Tue Jun 30, 12:31AM CDT
COPENHAGEN, Denmark - June 30, 2015 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH), has exercised several contract options for the development of a vaccine that accelerates and enhances the immune response against Marburgvirus, a member of the Filovirus family. The contract, originally awarded in 2012, will provide approximately USD 15 million in additional funds to bring the total value of the contract to approximately USD 33 million. The additional revenue will be recognized over the expanded contract period from 2015-2018.
Burkholderia Pseudomallei Infections - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fphp3w/burkholderia) has announced the addition of the "Burkholderia Pseudomallei Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Burkholderia Pseudomallei Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Burkholderia Pseudomallei Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Burkholderia Pseudomallei Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Burkholderia Pseudomallei Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Burkholderia Pseudomallei Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Burkholderia Pseudomallei Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Bavarian Nordic A/S - Emergent BioSolutions Inc. - Soligenix, Inc. - Syntiron LLC For more information visit http://www.researchandmarkets.com/research/fp...rkholderia
EBS: 32.58 (+0.39)
Global Anthrax Pipeline Review, H1 2015 - 33 Companies & 29 Drug Profiles
M2 - Mon Jun 08, 8:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nbhb3h/anthrax) has announced the addition of the "Anthrax - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anthrax, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anthrax and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Aradigm Corporation - Bavarian Nordic A/S - Bristol-Myers Squibb Company - ContraFect Corporation - Dynavax Technologies Corporation - Elusys Therapeutics, Inc. - Emergent BioSolutions Inc. - Evolva SA - Green Cross Corporation - Grifols, S.A. - Hawaii Biotech, Inc. - iBio, Inc. - Immunovaccine, Inc. - Innovative Biologics, Inc. - Microbiotix, Inc. - NanoBio Corporation - Navigen Pharmaceuticals, Inc. - Oragenics, Inc. - PaxVax - Pfenex Inc. - Planet Biotechnology Inc. - Protein Potential, LLC - ProThera Biologics, LLC. - PsiOxus Therapeutics, Ltd. - Revivicor, Inc. - SelectX Pharmaceuticals, Inc. - Soligenix, Inc. - Summit Corporation plc - Syntiron LLC - Tetraphase Pharmaceuticals Inc. - The Medicines Company - Vaxin, Inc. For more information visit http://www.researchandmarkets.com/research/nbhb3h/anthrax
DVAX: 31.68 (+1.19), TTPH: 8.69 (+0.33), EBS: 32.58 (+0.39), ADRO: 20.40 (+0.27), IBIO: 0.70 (-0.01), BMY: 59.22 (+0.47), SMMT: 11.98 (+0.27), PFNX: 21.51 (+0.09), OGEN: 2.55 (unch)
Bavarian Nordic issues Financial Calendar for 2016
Thomson Reuters ONE - Fri Sep 11, 1:30AM CDT
COPENHAGEN, Denmark - September 11, 2015 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced its financial calendar for the year 2016.
Bavarian Nordic Announces First Half 2015 Results
Thomson Reuters ONE - Tue Aug 25, 12:02AM CDT
COPENHAGEN, Denmark, August 25, 2015 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today publishes its interim financial results for the first half of 2015. Revenue for the period was DKK 624 million (2014: DKK 450 million), the income before interest and tax (EBIT) was a profit of DKK 85 million (2014: DKK 70 million loss) and the net profit was DKK 107 million (2014: DKK 54 million loss). Financial expectations for the full year are maintained.
Bavarian Nordic to Host First Half 2015 Results Conference Call
Thomson Reuters ONE - Wed Aug 19, 10:30AM CDT
COPENHAGEN, Denmark - August 19, 2015 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) will announce its 2015 first half results on Tuesday, August 25, 2015.
Bavarian Nordic Initiates Phase 1 Clinical Trial of MVA-BN(r) in Respiratory Syncitial Virus (RSV)
GlobeNewswire - Tue Aug 18, 9:09AM CDT
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced the initiation of a Phase 1 clinical study of its MVA-BN RSV vaccine candidate against respiratory syncytial virus (RSV), the first study to evaluate the vaccine candidate in humans.
Metastatic Hormone Refractory Prostate Cancer Pipeline Review, H1 2015 - Summarizes all the Dormant and Discontinued Pipeline Projects
M2 - Mon Aug 17, 8:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ffhfkg/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2015" report to their offering. Summary This, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2015', provides an overview of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and enlists all their major and minor projects Companies Mentioned - AB Science - AbbVie Inc. - Adamis Pharmaceuticals Corporation - Advaxis, Inc. - Ambrx, Inc. - Amgen Inc. - Arrowhead Research Corporation - AstraZeneca Plc - ATLAB Pharma SAS - Bavarian Nordic A/S - Bellicum Pharmaceuticals, Inc. - BIND Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - CellCentric Ltd - DexTech Medical AB - Eli Lilly and Company - Emergent BioSolutions Inc. - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - GenSpera, Inc. - GlaxoSmithKline Plc - GTx, Inc. - Johnson & Johnson - Karyopharm Therapeutics, Inc. - Medivation, Inc. - Millennium Pharmaceuticals, Inc. - NewLink Genetics Corporation - Novartis AG - Oncogenex Pharmaceuticals, Inc. - Oncolytics Biotech Inc. - Onyx Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/ffhfkg/metastatic
ARWR: 6.40 (+0.68), AMBX: (), ADMP: 4.48 (+0.18), MDVN: 95.48 (-0.65), JNJ: 92.93 (+0.21), NLNK: 51.03 (+1.84), ABBV: 59.35 (-0.23), ADXS: 16.51 (+0.55), ONCY: 0.58 (-0.04), EBS: 32.58 (+0.39), AMGN: 153.21 (+0.07), BIND: 5.05 (+0.13), LLY: 81.80 (+0.96), BMY: 59.22 (+0.47), GSK: 40.26 (+0.02), GTXI: 0.86 (+0.01), BLCM: 17.05 (-0.48), AZN: 33.30 (+0.02), CELGZ: 1.93 (+0.07), KPTI: 14.95 (+0.41), NVS: 96.55 (+0.28)
Metastatic Breast Cancer - Pipeline Review, H1 2015 - Reviews Key Pipeline Products Under Drug Profile Section
M2 - Fri Aug 14, 8:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2kdtzh/metastatic_breast) has announced the addition of the "Metastatic Breast Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Breast Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Key Topics Covered: - Introduction - Metastatic Breast Cancer Overview - Therapeutics Development - Therapeutics under Development by Companies - Therapeutics under Investigation by Universities/Institutes - Pipeline Products Glance - Products under Development by Companies - Products under Investigation by Universities/Institutes - Companies Involved in Therapeutics Development - Therapeutics Assessment - Drug Profiles - Recent Pipeline Updates - Dormant Projects - Discontinued Products - Product Development Milestones Companies Mentioned - AbbVie Inc. - Advaxis, Inc. - Advenchen Laboratories, LLC - AlphaVax, Inc. - Amarna Therapeutics B.V. - Amgen Inc. - AngioGenex, Inc. - Aphios Corporation - arGEN-X BV - Aslan Pharmaceuticals Pte. Ltd. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Bavarian Nordic A/S - Bayer AG - BIOCAD - Biocon Limited - BioMarin Pharmaceutical Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CASI Pharmaceuticals Inc. - Celgene Corporation - Celldex Therapeutics, Inc. - Celltrion, Inc. - Corcept Therapeutics Incorporated - Curadis GmbH - Daiichi Sankyo Company, Limited - Deciphera Pharmaceuticals, LLC - Dompe Farmaceutici S.p.A. - Eisai Co., Ltd. - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/2k...tic_breast
ADXS: 16.51 (+0.55), BMRN: 132.88 (-0.20), CLDX: 15.45 (+0.53), AMGN: 153.21 (+0.07), LLY: 81.80 (+0.96), CASI: 1.11 (-0.11), BMY: 59.22 (+0.47), AZN: 33.30 (+0.02), AVEO: 1.36 (unch), ABBV: 59.35 (-0.23), CORT: 5.06 (+0.01), CELGZ: 1.93 (+0.07)
Colon Cancer Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Colon Cancer and Enlists all Their Major and Minor Projects
M2 - Fri Aug 14, 8:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6lqjnr/colon_cancer) has announced the addition of the "Colon Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Colon Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colon Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Colon Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities Key Topics Covered: - Introduction - Colon Cancer Overview - Therapeutics Development - Therapeutics under Development by Companies - Therapeutics under Investigation by Universities/Institutes - Pipeline Products Glance - Products under Development by Companies - Products under Investigation by Universities/Institutes - Companies Involved in Therapeutics Development - Therapeutics Assessment - Drug Profiles - Recent Pipeline Updates - Dormant Projects - Discontinued Products - Product Development Milestones Companies Mentioned - Aduro BioTech, Inc. - Advanced Proteome Therapeutics Corporation - Advenchen Laboratories, LLC - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alethia Biotherapeutics Inc. - AlphaVax, Inc. - Ambrx, Inc. - Anavex Life Sciences Corp. - AndroScience Corporation - ANP Technologies, Inc. - Aphios Corporation - Apogenix GmbH - Aposense Ltd. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bavarian Nordic A/S - Bio-Path Holdings, Inc. - Bioncotech Therapeutics S.L. - Bionomics Limited - Carna Biosciences, Inc. - Celyad - Cold Genesys, Inc. For more information visit http://www.researchandmarkets.com/research/6l...lon_cancer
ADRO: 20.40 (+0.27), BPTH: 1.14 (-0.03), AMBX: (), AZN: 33.30 (+0.02), CYAD: 42.26 (-0.69)
Colorectal Cancer - Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Colorectal Cancer
M2 - Fri Aug 14, 5:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dvsdxp/colorectal_cancer) has announced the addition of the "Colorectal Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Colorectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colorectal Cancer and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - A review of the Colorectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Key Topics Covered: - Colorectal Cancer Overview - Therapeutics Development - Therapeutics under Development by Companies - Therapeutics under Investigation by Universities/Institutes - Pipeline Products Glance - Products under Development by Companies - Products under Investigation by Universities/Institutes - Companies Involved in Therapeutics Development - Therapeutics Assessment - Drug Profiles - Recent Pipeline Updates - Dormant Projects - Discontinued Products - Product Development Milestones Companies Mentioned - 2cureX ApS - 3-V Biosciences, Inc. - 4SC AG - AB Science - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Adamed Sp. z o.o. - Advaxis, Inc. - Advenchen Laboratories, LLC - Aeterna Zentaris Inc. - Alchemia Limited - Allinky Biopharma - Amgen Inc. - Angiogene Pharmaceuticals Limited - Antibe Therapeutics, Inc. - Aphios Corporation - Arisaph Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Bavarian Nordic A/S - Bayer AG - Beta Cat Pharmaceuticals, LLC - Biocon Limited - Bionomics Limited - BioNovion B.V. - Biothera, Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company For more information visit http://www.researchandmarkets.com/research/dv...tal_cancer
ADXS: 16.51 (+0.55), ARQL: 1.71 (-0.01), AMGN: 153.21 (+0.07), BMY: 59.22 (+0.47), ATNM: 2.44 (+0.07), AZN: 33.30 (+0.02), AVEO: 1.36 (unch), ABBV: 59.35 (-0.23), ARRY: 5.88 (-0.05)
Respiratory Syncytial Virus (RSV) Infections: Pipeline Review, H1 2015 - Summarizes all the Dormant and Discontinued Pipeline Projects
M2 - Thu Aug 13, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fswgvd/respiratory) has announced the addition of the "Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Respiratory Syncytial Virus (RSV) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Respiratory Syncytial Virus (RSV) Infections and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Respiratory Syncytial Virus (RSV) Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Respiratory Syncytial Virus (RSV) Infections and enlists all their major and minor projects Companies Mentioned - 3-V Biosciences, Inc. - Ablynx NV - ADMA Biologics, Inc. - Agilvax, Inc. - AlphaVax, Inc. - AmVac AG - Aridis Pharmaceuticals LLC - Artificial Cell Technologies, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Bavarian Nordic A/S - Biota Pharmaceuticals, Inc. - Celltrion, Inc. - Codagenix, Inc. - Crucell N.V. - CureVac GmbH - Emergent BioSolutions Inc. - Evec, Inc. - F. Hoffmann-La Roche Ltd. - GenVec, Inc. - Gilead Sciences, Inc. - GlaxoSmithKline Plc - Humabs BioMed SA - iBio, Inc. - Immunovaccine, Inc. - Johnson & Johnson - Kineta, Inc. - MedImmune, LLC - Medivir AB - Merck & Co., Inc. - Microbiotix, Inc. - MSM Protein Technologies, Inc. - Mucosis B.V. - NanoBio Corporation For more information visit http://www.researchandmarkets.com/research/fs...espiratory
ADMA: 9.35 (+0.36), EBS: 32.58 (+0.39), BOTA: 2.08 (-0.08), GSK: 40.26 (+0.02), JNJ: 92.93 (+0.21), GILD: 109.63 (+2.38), MRK: 52.09 (-0.63), AZN: 33.30 (+0.02), IBIO: 0.70 (-0.01)
Kerrisdale Capital Announces Follow-Up Conference Call to Discuss Short Thesis on Bavarian Nordic A/S
PR Newswire Europe - Wed Aug 12, 1:30AM CDT
Kerrisdale Capital, a private investment manager, will host a follow-up conference call on Tuesday, August 18th, at 11:00am EDT / 17:00 CEST, to further discuss its analysis of Bavarian Nordic A/S, whose prostate-cancer treatment candidate, Prostvac-VF, Kerrisdale believes is ineffective. The speakers will review the available clinical data on Prostvac and competing prostate-cancer vaccines from the last 15 years. They will also discuss recent developments affecting the commercial prospects of Bavarian Nordic's Ebola and smallpox vaccines.
Bladder Cancer Pipeline Review, H1 2015 - 80 Companies & 119 Drug Profiles
M2 - Fri Jul 31, 8:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/shdv3w/bladder_cancer) has announced the addition of the "Bladder Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bladder Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bladder Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - Advaxis, Inc. - Alligator Bioscience AB - Alnylam Pharmaceuticals, Inc. - Altor BioScience Corporation - Amgen Inc. - AndroScience Corporation - APIM Therapeutics AS - Arno Therapeutics, Inc. - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - AuraSense Therapeutics, LLC - AVEO Pharmaceuticals, Inc. - AvidBiotics Corp. - Bavarian Nordic A/S - Bayer AG - BioCancell Ltd - Bioncotech Therapeutics S.L. - Biotest AG - cCAM Biotherapeutics Ltd. - Celgene Corporation - Cold Genesys, Inc. - Daiichi Sankyo Company, Limited - Dompe Farmaceutici S.p.A. - DormaTarg, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EntreChem, S.L. - Esperance Pharmaceuticals, Inc. - Evotec AG - F. Hoffmann-La Roche Ltd. - Gene Signal International SA - Genmab A/S - GlaxoSmithKline Plc - Heat Biologics, Inc. For more information visit http://www.researchandmarkets.com/research/sh...der_cancer
HTBX: 4.52 (+0.11), ADXS: 16.51 (+0.55), AMGN: 153.21 (+0.07), LLY: 81.80 (+0.96), GSK: 40.26 (+0.02), AZN: 33.30 (+0.02), AVEO: 1.36 (unch), CELGZ: 1.93 (+0.07)
Bavarian Nordic Announces Initiation of NCI-sponsored Phase 2 Study of PROSTVAC in Patients with Localized Prostate Cancer
Thomson Reuters ONE - Fri Jul 24, 12:31AM CDT
- Multi-center, placebo-controlled study designed to explore PROSTVAC(R) in patients undergoing active surveillance
Bavarian Nordic Announces that the Oxford Vaccines Group has Initiated a Phase 2 Study of the Ebola Prime-Boost Vaccine Regimen Combining MVA-BN(r) Filo and Janssen's AdVac(r) Technology
GlobeNewswire - Wed Jul 15, 1:10AM CDT
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the Oxford Vaccines Group has initiated a Phase 2 clinical study of the Ebola prime-boost vaccine regimen that combines Bavarian Nordic's MVA-BN Filo vaccine with the Ad26.ZEBOV vaccine from the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen). The first volunteers have received their initial vaccine dose.
JNJ: 92.93 (+0.21)
Bavarian Nordic Receives Order for IMVAMUNE(R) Smallpox Vaccine from the U.S. Government Valued at USD 133 Million
Thomson Reuters ONE - Tue Jul 07, 12:01AM CDT
- Bulk supply order will help maintain current stockpile and serves as a precursor for future contracts for freeze-dried formulation of IMVAMUNE
Bavarian Nordic Announces Option Exercise by U.S. Government for Development of Filovirus Vaccine
Thomson Reuters ONE - Tue Jun 30, 12:31AM CDT
COPENHAGEN, Denmark - June 30, 2015 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH), has exercised several contract options for the development of a vaccine that accelerates and enhances the immune response against Marburgvirus, a member of the Filovirus family. The contract, originally awarded in 2012, will provide approximately USD 15 million in additional funds to bring the total value of the contract to approximately USD 33 million. The additional revenue will be recognized over the expanded contract period from 2015-2018.
Burkholderia Pseudomallei Infections - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fphp3w/burkholderia) has announced the addition of the "Burkholderia Pseudomallei Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Burkholderia Pseudomallei Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Burkholderia Pseudomallei Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Burkholderia Pseudomallei Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Burkholderia Pseudomallei Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Burkholderia Pseudomallei Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Burkholderia Pseudomallei Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Bavarian Nordic A/S - Emergent BioSolutions Inc. - Soligenix, Inc. - Syntiron LLC For more information visit http://www.researchandmarkets.com/research/fp...rkholderia
EBS: 32.58 (+0.39)
Global Anthrax Pipeline Review, H1 2015 - 33 Companies & 29 Drug Profiles
M2 - Mon Jun 08, 8:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nbhb3h/anthrax) has announced the addition of the "Anthrax - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anthrax, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anthrax and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aduro BioTech, Inc. - Aradigm Corporation - Bavarian Nordic A/S - Bristol-Myers Squibb Company - ContraFect Corporation - Dynavax Technologies Corporation - Elusys Therapeutics, Inc. - Emergent BioSolutions Inc. - Evolva SA - Green Cross Corporation - Grifols, S.A. - Hawaii Biotech, Inc. - iBio, Inc. - Immunovaccine, Inc. - Innovative Biologics, Inc. - Microbiotix, Inc. - NanoBio Corporation - Navigen Pharmaceuticals, Inc. - Oragenics, Inc. - PaxVax - Pfenex Inc. - Planet Biotechnology Inc. - Protein Potential, LLC - ProThera Biologics, LLC. - PsiOxus Therapeutics, Ltd. - Revivicor, Inc. - SelectX Pharmaceuticals, Inc. - Soligenix, Inc. - Summit Corporation plc - Syntiron LLC - Tetraphase Pharmaceuticals Inc. - The Medicines Company - Vaxin, Inc. For more information visit http://www.researchandmarkets.com/research/nbhb3h/anthrax
DVAX: 31.68 (+1.19), TTPH: 8.69 (+0.33), EBS: 32.58 (+0.39), ADRO: 20.40 (+0.27), IBIO: 0.70 (-0.01), BMY: 59.22 (+0.47), SMMT: 11.98 (+0.27), PFNX: 21.51 (+0.09), OGEN: 2.55 (unch)
